Kilian L. Kleemann

Kilian L. Kleemann

Auto-generated profile, based on publicly available information

Kilian L. Kleemann

Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ZYZhuoran Yin
Zhuoran Yin
SHShawn Herron
Shawn Herron
SSSebastian Silveira
Sebastian Silveira
KKKilian Kleemann
Kilian Kleemann
CGChristian Gauthier
Christian Gauthier
OBOleg Butovsky
Oleg Butovsky

9 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
KKKimitoshi Kimura
Kimitoshi Kimura
ASAyshwarya Subramanian
Ayshwarya Subramanian
ZYZhuoran Yin
Zhuoran Yin
AKAhad Khalilnezhad
Ahad Khalilnezhad
YWYufan Wu
Yufan Wu
VKVijay K. Kuchroo
Vijay K. Kuchroo

28 November 2025 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
OBOleg Butovsky
Oleg Butovsky
NRNeta Rosenzweig
Neta Rosenzweig
KKKilian L. Kleemann
Kilian L. Kleemann
MJMehdi Jorfi
Mehdi Jorfi
VKVijay K. Kuchroo
Vijay K. Kuchroo
HWHoward L. Weiner
Howard L. Weiner

22 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GMGabriel L. McKinsey
Gabriel L. McKinsey
NSNicolas Santander
Nicolas Santander
XZXiaoming Zhang
Xiaoming Zhang
KKKilian L. Kleemann
Kilian L. Kleemann
LTLauren Tran
Lauren Tran
TAThomas D. Arnold
Thomas D. Arnold
Microglial diversity arises from the interplay between inherent genetic programs and external environmental signals. However, the mechanisms by which these processes develop and interact within the growing brain are not yet fully understood. Here, we show that radial glia-expressed integrin beta 8 (ITGB8) activates microglia-expressed TGFβ1 to drive microglial development. Domain-restricted deletion of Itgb8 in these progenitors results in regionally restricted and developmentally arrested microglia that persist into adulthood. In the absence of autocrine TGFβ1 signaling, microglia adopt a similar phenotype, leading to neuromotor symptoms almost identical to Itgb8 mutant mice. In contrast, microglia lacking the canonical TGFβ signal transducers Smad2 and Smad3 have a less polarized dysmature phenotype and correspondingly less severe neuromotor dysfunction. Our study describes the spatio-temporal regulation of TGFβ activation and signaling in the brain necessary to promote microglial development, and provides evidence for the adoption of microglial developmental signaling pathways in brain injury or disease.

15 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
WBWesley Brandao
Wesley Brandao
NJNimansha Jain
Nimansha Jain
ZYZhuoran Yin
Zhuoran Yin
KKKilian L. Kleemann
Kilian L. Kleemann
MCMadison Carpenter
Madison Carpenter
OBOleg Butovsky
Oleg Butovsky
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild dementia due to AD. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays an important role in disease onset and progression. Thus, a major question is how to modulate the phenotype and function of microglia to treat AD. Xenon (Xe) gas is a noble gas used in human patients as an anesthetic and a neuroprotectant used for treating brain injuries. Xe penetrates the blood-brain barrier, which could make it an effective therapeutic. To assess the effect of Xe on microglia and AD pathology, we designed a custom Xe inhalation chamber and treated several mouse models of AD with Xe gas. Xe treatment induced mouse microglia to adopt an intermediate activation state that we have termed pre–neurodegenerative microglia (pre-MGnD). This microglial phenotypic transition was observed in mouse models of acute neurodegeneration and amyloidosis (APP/PS1 and 5xFAD mice) and tauopathy (P301S mice). This microglial state enhanced amyloid plaque compaction and reduced dystrophic neurites in the APP/PS1 and 5xFAD mouse models. Moreover, Xe inhalation reduced brain atrophy and neuroinflammation and improved nest-building behavior in P301S mice. Mechanistically, Xe inhalation induced homeostatic brain microglia toward a pre-MGnD state through IFN-γ signaling that maintained the microglial phagocytic response in APP/PS1 and 5xFAD mice while suppressing the microglial proinflammatory phenotype in P301S mice. These results support the translation of Xe inhalation as an approach for treating AD.

3 August 2026 in Immunity
Verified
Journal Article
Open access
CBChristopher D. Balak
Christopher D. Balak
JSJohannes C.M. Schlachetzki
Johannes C.M. Schlachetzki
ALAddison J. Lana
Addison J. Lana
EWElizabeth West
Elizabeth West
CHChristine Hong
Christine Hong
CGChristopher K. Glass
Christopher K. Glass